Skip to content
value.today
Total raised
$35 M
2 rounds on record
Latest round
$8 M
Dec 2010
First round on record
Aug 2009
Today
Private
No later event on record

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Endocyte Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Dec 2010$8 MNo. 2$2 to $10 million

Endocyte Inc.: Raise no. 2, Dec 2010

Investors in this round

3 investors had bought by the notice of Dec 23, 2010: 3 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 16 investors are named for Endocyte Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$8 M of $15 M offered; $7 M still to sell
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Michael A. Sherman · Executive Officer
  • P. Ron Ellis · Executive Officer, Director
  • Ann F. Hanham · Director
  • Douglas G. Bailey · Director
  • Fred A. Middleton · Director
  • James S. Shannon · Director
  • John C. Aplin · Director
  • John C. Clawson · Director
  • Keith E. Brauer · Director
  • Philip S. Low · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Michael A. Sherman, Chief Financial Officer. Source: SEC Form D, newest notice filed Dec 23, 2010. Read the notice at the SEC.

debt, optionsSEC
Aug 2009$27 MNo. 1$10 to $50 million

Endocyte Inc.: Raise no. 1, Aug 2009

Investors in this round

28 investors had bought by the notice of Oct 26, 2009: 28 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 16 investors are named for Endocyte Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$27 M of $30 M offered; $3 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Mike A. Sherman · Executive Officer
  • P. Ron Ellis · Executive Officer, Director
  • Ann F. Hanham · Director
  • Douglas B. Bailey · Director
  • Fred A. Middleton · Director
  • Jack B. Clawson · Director
  • John C. Aplin · Director
  • Keith B. Brauer · Director
  • Philip S. Low · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Total Offering Amount: $30,000,002.00 Total Amount Sold: $26,645,523.75 Total Remaining to be Sold: $3,345,478.25”

Signed by Mike Sherman, Chief Financial Officer. Source: SEC Form D and 1 amendment, newest notice filed Oct 26, 2009. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Endocyte Inc. chose not to state its revenue in its newest notice of a funding round (Dec 2010).

    SEC Form D · Dec 2010

  • The industry group it chose in its notices: Other.

    SEC Form D · Dec 2010

That is all the official record says: Endocyte Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

16 named in official filings. Open an investor to see everything it has backed.

Investors in Endocyte Inc.
InvestorKindAmountRoundRoleSource
Cincinnati Financial CorpFund or asset managernot statednot statedHeld Series B, C-1, C-2 and C-3 preferred stock, 10% owner (Form 3, 2011)SEC Form 3
Douglas G. BaileyPersonnot statednot statedHeld Series C-3 preferred stock, director (Form 3, 2011)SEC Form 3
John G. ClawsonPersonnot statednot statedHeld Series A-1 and C-3 preferred stock, director (Form 3, 2011)SEC Form 3
Pension Fund of the Christian Church (Disciples of Christ) IncFund or asset managernot statednot statedHeld Series C-2 and C-3 preferred stock, 10% owner (Form 3, 2011)SEC Form 3
P. Ron EllisPersonnot statednot statedHeld Series A-1 preferred stock, director (Form 3, 2011)SEC Form 3
Sanderling V Beteiligungs Gmbh & Co KGCompanynot statednot statedHeld Series B, C-1, C-2 and C-3 preferred stock, 10% owner (Form 3, 2011)SEC Form 3
Sanderling V Biomedical Co Investment Fund LPFund or asset managernot statednot statedHeld Series B, C-1, C-2 and C-3 preferred stock, 10% owner (Form 3, 2011)SEC Form 3
Sanderling V Biomedical LPFund or asset managernot statednot statedHeld Series B, C-1, C-2 and C-3 preferred stock, 10% owner (Form 3, 2011)SEC Form 3
Sanderling Venture Partners V Co Investment Fund, LPVenture capitalnot statednot statedHeld Series B, C-1, C-2 and C-3 preferred stock, 10% owner (Form 3, 2011)SEC Form 3
Sanderling Venture Partners VI Co Investment Fund LPVenture capitalnot statednot statedHeld Series B, C-1, C-2 and C-3 preferred stock, 10% owner (Form 3, 2011)SEC Form 3
Sanderling Venture Partners V, LPVenture capitalnot statednot statedHeld Series B, C-1, C-2 and C-3 preferred stock, 10% owner (Form 3, 2011)SEC Form 3
Sanderling Ventures Management VVenture capitalnot statednot statedHeld Series B, C-1, C-2 and C-3 preferred stock, 10% owner (Form 3, 2011)SEC Form 3
Sanderling Ventures Management VIVenture capitalnot statednot statedHeld Series B, C-1, C-2 and C-3 preferred stock, 10% owner (Form 3, 2011)SEC Form 3
Sanderling VI Beteiligungs GmbH & Co KGCompanynot statednot statedHeld Series B, C-1, C-2 and C-3 preferred stock, 10% owner (Form 3, 2011)SEC Form 3
Sanderling VI Limited PartnershipFund or asset managernot statednot statedHeld Series B, C-1, C-2 and C-3 preferred stock, 10% owner (Form 3, 2011)SEC Form 3
Sanderling V LTD PartnershipFund or asset managernot statednot statedHeld Series B, C-1, C-2 and C-3 preferred stock, 10% owner (Form 3, 2011)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 28 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Endocyte Inc.
NameRoleNamed in
Michael A. ShermanExecutive officerDec 2010
P. Ron EllisExecutive officerDec 2010
Mike A. ShermanExecutive officerOct 2009
Mike ShermanExecutive officerAug 2009
Ann F. HanhamDirectorDec 2010
Douglas G. BaileyDirectorDec 2010
Fred A. MiddletonDirectorDec 2010
James S. ShannonDirectorDec 2010
John C. AplinDirectorDec 2010
John C. ClawsonDirectorDec 2010
Keith E. BrauerDirectorDec 2010
P. Ron EllisDirectorDec 2010
Philip S. LowDirectorDec 2010
Douglas B. BaileyDirectorOct 2009
Jack B. ClawsonDirectorOct 2009
Keith B. BrauerDirectorOct 2009
Jack ClawsonDirectorAug 2009
Keith BrauerDirectorAug 2009